Cenova Capital
Shanghai, Shanghaicenovaventures.com
Overview
One the earliest healthcare dedicated funds in China, Cenova Capital was established in 2010 to provide thoughtful and connected capital to transform China's healthcare industry. As a value-oriented investor, Cenova uses a methodical, research-based approach to uncover unique proprietary investment opportunities, and build synergies across its portfolio. Cenova has four funds under management with a combined AUM of over USD600 million invested in over 40 companies in the life sciences and healthcare product and services sectors, including directly or indirectly more than 30 hospitals in Mainland China.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Accro Bioscience Inc. | May 2026 | Series C | Co-investor |
| Accro Bioscience Inc. | May 2026 | Series C | Co-investor |
| Vivace Therapeutics | Mar 2025 | Series D | Co-investor |
| Zhejiang Weimeng Hospital Management Co., Ltd. | Jan 2025 | Series D Extension | Co-investor |
| Jiangsu Jland Biotech Co., Ltd. | Sep 2023 | Series B | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
